Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04410731 · ClinicalTrials.gov registry record · Phase 1

Allogeneic BM-MSCs in Patients with Lumbar Facet Arthropathy

A Phase 1 study of Facet-Mediated Low Back Pain, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT04410731 is a Phase 1 study of Facet-Mediated Low Back Pain that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04410731, a Phase 1 study of Facet-Mediated Low Back Pain, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Researchers are conducting this study to learn more about the side effects of bone marrow-derived stem cells when injected into the facet joints for the treatment of painful lumbar facet joint arthropathies.

Interventions

  • DRUG Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy

Study Locations (1)

Florida

  • Mayo Clinic in Florida - Jacksonville

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-04-28
Est. Completion 2024-03-15
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT04410731

The ClinicalTrials.gov registry entry for NCT04410731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Facet-Mediated Low Back Pain appearing as the primary indexed condition, and to 1 intervention - of which Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy is the first listed.

NCT04410731 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04410731 about?

NCT04410731 is a clinical study titled "Allogeneic BM-MSCs in Patients with Lumbar Facet Arthropathy". Researchers are conducting this study to learn more about the side effects of bone marrow-derived stem cells when injected into the facet joints for the treatment of painful lumbar facet joint arthropathies.

What is the current status of trial NCT04410731?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-04-28. Estimated completion is 2024-03-15.

What conditions does trial NCT04410731 study?

This clinical trial studies the following conditions: Facet-Mediated Low Back Pain.

What interventions are being tested in trial NCT04410731?

The interventions under investigation include: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy (DRUG).

Who is sponsoring clinical trial NCT04410731?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04410731 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Facet-Mediated Low Back Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.